Logivir 400 DT Tablet contains Acyclovir 400 mg, an antiviral agent effective against herpes simplex virus types 1 and 2, varicella-zoster virus, and other susceptible viral infections. Acyclovir acts by inhibiting viral DNA polymerase, thereby preventing viral replication and reducing the severity and duration of viral outbreaks. Logivir 400 DT is indicated for the treatment of herpes simplex infections, including genital herpes, cold sores, and herpes labialis, as well as for the management of varicella (chickenpox) and herpes zoster (shingles). The tablet is designed to be dispersible, facilitating easier administration and rapid absorption, which enhances patient compliance, especially in those with swallowing difficulties. Dosage and duration of therapy depend on the type and severity of infection, as well as patient-specific factors such as renal function. Common adverse effects may include headache, nausea, diarrhea, and occasional renal toxicity, particularly in patients with pre-existing kidney impairment. It is essential to maintain adequate hydration during therapy to minimize renal side effects. Logivir 400 DT should be used under medical supervision, and patients should be advised to complete the full course of treatment to prevent viral resistance and recurrence. This medication is contraindicated in patients with known hypersensitivity to acyclovir or valacyclovir.